Isturisa (osilodrostat)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- osilodrostat
- Company
- Recordati Rare Diseases
- Status
- Authorised
- Therapeutic area
- Cushing Syndrome
- CHMP opinion
- Thu 14 Nov 2019
- EU approval
- Thu 09 Jan 2020
- Designations
- Orphan
- Application
- EMEA/H/C/004821
- ATC
- H02CA02
- Official record
- www.ema.europa.eu
Indication
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
Regulatory milestones
No milestones recorded in the last year.
Follow Isturisa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.